 |
인쇄하기
취소
|
KFDA to assess safety of clevudine
Now all eyes are on the Korea Food and Drug Administration Committee’s decision on the safety problems of Levovir (clevudine), an investigatory hepatitis B treatment.
The KFDA will be given advice from the Central Pharmaceutical Affairs Review Committee for the drug safety on May 7.
It's still unclear how much influence the decision will bring to Levovir, but sources say the KFDA will not...
The KFDA will be given advice from the Central Pharmaceutical Affairs Review Committee for the drug safety on May 7.
It's still unclear how much influence the decision will bring to Levovir, but sources say the KFDA will not...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.